中文摘要：

目的探讨三阴乳腺癌（TNBC）与非三阴乳腺癌（non—TNBC）接受表阿霉素联合多西紫杉醇方案（ET方案）的化疗敏感性及预后方面的差别。方法对接受ET新辅助化疗方案治疗的249例乳腺癌患者进行回顾性分析。依据免疫组化雌激素受体（ER）、孕激素受体（PR）、表皮生长因子受体2（HER2）表达水平将乳腺癌分为三阴乳腺癌及非三阴乳腺癌两类，分析三阴与非三阴乳腺患者接受ET新辅助化疗方案后，二者病理疗效及远期生存的差别。结果249例患者中，54（21．7％）例为三阴乳腺癌，195（78．3％）例为非三阴乳腺癌。三阴乳腺癌的病理完全缓解（pCR）率为25．9％，明显高于非三阴乳腺癌的12.3％（P=0．019）。三阴乳腺癌患者，特别是新辅助化疗后仍有癌残留的患者，其5年无病生存率（DFS）及5年的总生存率（OS）均明显低于非三阴乳腺癌（P值均〈0．05）。获得pCR的乳腺癌患者5年的DFS和0S均明显高于化疗后仍有癌残留的患者（P值均〈0．05）。获得pCR的三阴乳腺癌与非三阴乳腺癌患者的DFS（P=0．837）及OS（P=0．398）均无统计学差异。结论：本研究结果表明，相比于非三阴乳腺癌患者，三阴乳腺癌患者具有更高的病理完全缓解率，但预后却较差。

英文摘要：

Objective To compare the response to neoadjuvant epirubicin plus docetaxel chemotherapy and survival in patients with Triple-negative breast cancer （TNBC） and non-TNBC. Methods Two hundred and forty-nine patients treated with neoadjuvant chemotherapy were included in this retrospective study. All the patients were classified as TNBC and non-TNBC according the immunohistochemieal results of estrogen receptor （ER）, progesterone receptor （PR） and HER2 status. TNBC is defined as the lack of ER, PR, and HER-2 expression. The pathological response and long time survival were compared between TNBC patients and non-TNBC patients. Results Among all 249 cases, 54 （21.7%）were TNBC patients, 195 （78.3%）were non-TNBC patients. Compared with non- TNBC patients, the pathological complete response （pCR） rate of patients with TNBC was 25.9%,＇ which was significantly higher than that of patients with non-TNBC （P=0.019）. Patients with TNBC especially for those with residual disease after chemotherapy had decreased 5 years＇ disease-free survival （DFS） and 5 years＇ overall survival （OS） compared with those with non-TNBC（P〈0.05）. The 5 years＇ DFS and OS of patients who achieve pCR were significantly higher than that of patients with residual disease after chemotherapy （P〈0.05）. Patients with TNBC and non-TNBC had similar DFS and OS if pCR achieved. Conclusion Patients with TNBC were more sensitive to neoadjuvant docetaxel plus epirubicin chemotherapy. Compared with non-TNBC patients, TNBC patients had increased pCR rate, but were associated with significantly worse survival.